Welcome to Transcell

Regenerative Medicine


Regenerative medicine holds the promise of affordable health care solutions with stem cells as the biological tools repairing and regenerating the damaged tissues of the human body. This field of medicine refers to developing completely new ways to treat and manage chronic diseases such as diabetes, infarctions, degenerative nerve, bone, joint conditions and autoimmune dysfunctions. Addressing cancers through regenerative medicine route is altogether a novel and advanced medical approach in managing the very disease itself.

The following are the off the shelf lead regenerative product candidates that Transcell is working on:

Product Candidates Program Stage of development
Mesendron? Allogenic dendritic cell-Mesenchymal stem cell based product formulation targeted delivery to treat Ovarian cancers. Preclinical
TransM? - (This product candidate has the potential for Orphan drug designation) Duschenne Muscular Dystrophies Pilot trial
TransPD? Periodontal diseases are infections of the structures around the teeth, which include the gums, periodontal ligament and alveolar bone. In severe forms of the disease, all of the tissues are involved leading to dysfunction of the entire oral environment. Pilot trial
Transchymal? Autoimmune diseases arise from an abnormal immune response of the body against substances and tissues normally present in the body (autoimmunity). This may be restricted to certain organs (e.g. in autoimmune thyroiditis) or involve a particular tissue in different places. Examples: Rheumatoid Arthritis, Psoriasis, Vitiligo, Muscular dystrophies, Diabetes type 1, Eczema, Multiple Sclerosis etc. The treatment of autoimmune diseases is typically with immune-suppression?medication that decreases the immune response Preclinical

Transcell collaborates with medical community to develop better health care and difficult diseases management through it?s flagship platform of stem cell technologies. The in-house customized research and development in the laboratory are translated to clinical practice, from bench to bedside through regulated protocols compliant with the regime of land.

We are building strategic alliances across clinical and manufacturing areas to enhance our success rate in the market.